1. Home
  2. ZLAB vs SIGA Comparison

ZLAB vs SIGA Comparison

Compare ZLAB & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • SIGA
  • Stock Information
  • Founded
  • ZLAB 2013
  • SIGA 1995
  • Country
  • ZLAB China
  • SIGA United States
  • Employees
  • ZLAB N/A
  • SIGA N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • SIGA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZLAB Health Care
  • SIGA Health Care
  • Exchange
  • ZLAB Nasdaq
  • SIGA Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • SIGA N/A
  • IPO Year
  • ZLAB 2017
  • SIGA 1997
  • Fundamental
  • Price
  • ZLAB $29.24
  • SIGA $5.62
  • Analyst Decision
  • ZLAB Buy
  • SIGA
  • Analyst Count
  • ZLAB 4
  • SIGA 0
  • Target Price
  • ZLAB $47.37
  • SIGA N/A
  • AVG Volume (30 Days)
  • ZLAB 1.2M
  • SIGA 576.4K
  • Earning Date
  • ZLAB 05-08-2025
  • SIGA 05-08-2025
  • Dividend Yield
  • ZLAB N/A
  • SIGA 10.58%
  • EPS Growth
  • ZLAB N/A
  • SIGA N/A
  • EPS
  • ZLAB N/A
  • SIGA 0.67
  • Revenue
  • ZLAB $418,326,000.00
  • SIGA $120,330,310.00
  • Revenue This Year
  • ZLAB $44.43
  • SIGA N/A
  • Revenue Next Year
  • ZLAB $48.68
  • SIGA $95.35
  • P/E Ratio
  • ZLAB N/A
  • SIGA $8.45
  • Revenue Growth
  • ZLAB 43.72
  • SIGA N/A
  • 52 Week Low
  • ZLAB $15.65
  • SIGA $4.95
  • 52 Week High
  • ZLAB $39.77
  • SIGA $12.83
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 42.71
  • SIGA 42.98
  • Support Level
  • ZLAB $27.61
  • SIGA $5.21
  • Resistance Level
  • ZLAB $32.02
  • SIGA $5.64
  • Average True Range (ATR)
  • ZLAB 1.23
  • SIGA 0.21
  • MACD
  • ZLAB -0.18
  • SIGA -0.09
  • Stochastic Oscillator
  • ZLAB 23.41
  • SIGA 16.43

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: